Home › NCT07492927

Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

Who can join

Ages 18 and older · Men

Inclusion Criteria:

1. Blood prostate-specific antigen PSA\>4ng/dl;
2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.
3. The patient is willing to undergo prostate biopsy.

Exclusion Criteria:

1. Previous diagnosis of prostate cancer through prostate biopsy;
2. History of other malignant tumors in the past two years;
3. According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment

About the study

The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.

Sponsor: Xijing Hospital · Participants: 1,700 · Started: Mar 12, 2021

Contact the study team

• Jianhua Jiao, MD. · Phone: +86 029 84771062

Official record on ClinicalTrials.gov — NCT07492927

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.